ESGCT 2022 – Sangamo strengthens its case in Fabry
The group looks like the gene therapy contender to beat, but that is not saying much.
Idorsia’s Fabry flop puts focus on gene therapies
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Upcoming events – US approval verdicts for Opdivo and Galafold
The Bristol-Myers Squibb and Amicus drugs face approval decisions next week.